Clinical trial NCT05430178: Metabolic Pathology of Pediatric NAFLD
Official title: Understanding the Metabolic Pathology of Pediatric Obesity and NAFLD
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Nonalcoholic Fatty Liver
Nonalcoholic Steatohepatitis
Obesity
Lead sponsor: University of Oklahoma
Sponsor class: OTHER
Collaborators: name: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
First posted: 2022-06-24
Enrollment: 100
Sex: ALL
Minimum age (years): 10
Maximum age (years): 20
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Cross-sectional design in which all participants receive all interventions in the form of short-term observations following oral consumption of test materials.
Primary purpose: BASIC_SCIENCE

Brief summary: Nonalcoholic fatty liver disease (NAFLD) is now the most common liver disease worldwide and affects nearly 40% of obese youth and up to 10% of the general pediatric population. Some features of NAFLD are similar in children and adults, yet fibrosis and inflammation are more common in the portal zone and occur earlier in pediatric NAFLD patients than adults. This portends a rapid progression to end-stage liver disease in early adulthood. For the majority of children with NAFLD, mechanisms driving the origin and rapid progression of disease remain unknown. Thus, there is a critical, unmet need to study the specific underlying patterns of metabolic and molecular changes in the liver underlying the development and progression unique to children with NAFLD.

This proposal will test the hypotheses that children with NAFLD have excess glucose and lipid produced by the liver, that those events are regulated by specific variations in the amount and location of RNAs and proteins in liver, and that the concentration of specific micro-RNAs in the blood can be used as a biomarker for NAFLD in pediatric patients.

Detailed description: This project uses a cross-sectional design with a single testing period without a formal intervention (e.g., diet, drug, exercise) or natural follow-up period. Participants with nonalcoholic fatty liver disease (NAFLD), and age-matched control groups classified as either obese (Ob control) or normal weight (NW control) will complete all metabolic and descriptive tests, including blood analyses.

The NAFLD group will also have a liver biopsy as part of their standard clinical care; a portion of the biopsy will be used for the research testing. The Ob and NW control groups will not undergo liver biopsy. To provide a set of reference liver samples to compare with the NAFLD group, we will enroll a "liver control" group, consisting of age-matched patients who are scheduled to have a cholecystectomy with liver biopsy or are undergoing liver resection for tumor removal.

Eligibility criteria: Inclusion Criteria:

* Age: All participants must be 10.0 to 20.9 years old at the time of enrollment.
* Sex: Male and Female participants are eligible.
* Race/Ethnicity: Participants of all racial/ethnic identities will be recruited.
* Body mass index (BMI): Participants must be either in the normal weight (NW control group) or obese \[Ob control, nonalcoholic fatty liver disease (NALFD) groups\] range for BMI percentile. BMI percentile will be calculated from age- and sex-specific growth charts for children.
* NAFLD status: The NAFLD group participants will be eligible if they are scheduled for liver biopsy for clinical reasons and their histopathology report confirms a diagnosis of NAFLD. NW control, and Ob control, and Liver control participants must not have diagnosed NAFLD.

Exclusion Criteria:

* Chronic illness: Participants will not be able to participate if they have conditions that are likely to affect metabolic variables (either directly or due to required medications) or result in them being unable to complete the required tests. Such conditions could include, but are not limited to, untreated hypothyroidism or other endocrine disorders, rheumatoid arthritis requiring steroids or limiting mobility, cardiovascular disease, stroke, or cardiac failure, neurological disorders such as multiple sclerosis, cancer, liver diseases other than NAFLD (e.g., Wilson's disease), other organ disorders, or orthopedic conditions that limit physical activity.
* Acute illness: Participants will not be able to participate if they develop acute conditions that are likely to affect metabolic outcomes (either directly or due to required medications) or result in them being unable to participate; e.g., respiratory illness, infectious disease, fever, accident resulting in bone fractures, myocardial infarction, major depression. If such conditions resolve and there are no longer risks or likelihood of adverse effect on the study outcomes, participants may be rescheduled for testing.
* Medications and nutritional supplements: Medications, vitamins, or supplements that have known effects on the primary outcomes will be cause for exclusion. Examples include weight loss medications, glucocorticoids, or experimental medications used to correct a metabolic or hepatic condition. Medications used to control asthma, allergies, anxiety, depression, attention deficit disorder, menstrual cycle, hypothyroidism, gastric reflux, hypertension, and sleep will be allowed. Participants who are taking medications for treatment of acute illness or conditions such as cold, flu, injury, or infection will be rescheduled after they complete their treatment course.
* Pregnancy: Evidence of pregnancy or intent to become pregnant during the study is cause for exclusion.
* Smoking, alcohol abuse, or illicit drug abuse: Participants who smoke or have signs or symptoms of alcohol or substance abuse will be excluded.

Primary outcomes:
measure: De novo lipogenesis
timeFrame: Day 1
measure: Gluconeogenesis
timeFrame: Day 1
measure: Serum microRNA
timeFrame: Day 1
measure: Abundance of liver collagen
timeFrame: Day 1
measure: Liver mitochondrial flux
timeFrame: Day 1
measure: Insulin sensitivity
timeFrame: Day 1
Secondary outcomes:
measure: Targets of microRNA-122
timeFrame: Day 1
measure: Liver transcriptomics
timeFrame: Day 1
Other outcomes:
measure: Blood pressure
timeFrame: Day 1
measure: Arterial stiffness
timeFrame: Day 1
measure: Body composition
timeFrame: Day 1
measure: Cardiorespiratory fitness
timeFrame: Day 1
measure: Blood DNA analysis
timeFrame: Day 1
measure: Liver steatosis
timeFrame: Day 1
measure: Liver fibrosis
timeFrame: Day 1
Locations:
city: Oklahoma City
country: United States
facility: University of Oklahoma Health Sciences Center
state: Oklahoma
Study officials:
affiliation: University of Oklahoma
name: Kevin Short, PhD
role: PRINCIPAL_INVESTIGATOR
References: